COSMOS Pharmaceutical (3349) Q4 2026 earnings summary

Executive summary

• Net sales rose 8.7% year-over-year to ¥1,099,583 million, with operating profit up 4.8% to ¥42,353 million and profit attributable to owners of parent up 3.4% to ¥32,046 million.

• 105 new stores were opened across multiple regions, bringing the total to 1,708 stores at fiscal year-end.

• The company focused on cost efficiency and expanding its store network despite inflation and geopolitical risks.

Financial highlights

• EBITDA increased 6.8% year-over-year to ¥64,996 million.

• Ordinary profit grew 3.4% to ¥44,614 million.

• Comprehensive income reached ¥32,181 million, up 3.9% year-over-year.

• Cash flows from operating activities were ¥58,790 million, up 12.1% year-over-year.

• Net assets increased 10.2% to ¥283,700 million; total assets rose 13.7% to ¥596,485 million.

Outlook and guidance

• For the fiscal year ending May 31, 2027, net sales are forecast at ¥1,190,000 million (+8.2%), operating profit at ¥43,000 million (+1.5%), and profit attributable to owners of parent at ¥30,700 million (–4.2%).

• Continued store expansion is planned, especially in Kyushu, Chugoku, Shikoku, and new areas in Kanto, Chubu, and Kansai.

• Annual dividend forecast for FY2027 is ¥84 per share, up ¥2 from the previous year.